Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $559.9 million.

  • Keros Therapeutics' Cash & Equivalents rose 30.68% to $693.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $693.5 million, marking a year-over-year increase of 30.68%. This contributed to the annual value of $559.9 million for FY2024, which is 69.09% up from last year.
  • Keros Therapeutics' Cash & Equivalents amounted to $559.9 million in FY2024, which was up 69.09% from $331.1 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Cash & Equivalents registered a high of $559.9 million during FY2024, and its lowest value of $230.0 million during FY2021.
  • For the 3-year period, Keros Therapeutics' Cash & Equivalents averaged around $390.0 million, with its median value being $331.1 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first spiked by 3,687.41% in 2020, then declined by 13.48% in 2021.
  • Over the past 5 years, Keros Therapeutics' Cash & Equivalents (Yearly) stood at $265.9 million in 2020, then dropped by 13.48% to $230.0 million in 2021, then increased by 21.30% to $279.0 million in 2022, then rose by 18.67% to $331.1 million in 2023, then surged by 69.09% to $559.9 million in 2024.